Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.39 |
| ▸ | CDC7 | O00311 | 7/20 | 0.38 |
| ▸ | CYP11B2 | P19099 | 10/20 | 0.38 |
| ▸ | CYP11B1 | P15538 | 9/20 | 0.38 |
| ▸ | CDK2 | P24941 | 4/20 | 0.37 |
| ▸ | MAP3K14 | Q99558 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | GLA | P06280 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30961068 | 0.76 | KMO (0.36) | HRH4CDC7CDK2MAP3K14KDM4E | |
| SCHEMBL30013514 | 0.76 | KDM4E (0.35) | KDM4E | |
| SCHEMBL29909014 | 0.74 | TNKS2 (0.40) | KDM4E | |
| SCHEMBL30546468 | 0.72 | NQO1 (0.35) | HRH4CYP11B2CYP11B1 | |
| SCHEMBL30146470 | 0.71 | MAPT (0.38) | CDC7CDK2 | |
| SCHEMBL30013412 | 0.69 | CYP11B2 (0.38) | CYP11B2CYP11B1KDM4E | |
| SCHEMBL23601193 | 0.68 | ABCG2 (0.44) | KDM4EALDH1A1GLAGAA | |
| SCHEMBL30920907 | 0.67 | MAPT (0.36) | KDM4E | |
| SCHEMBL7431709 | 0.66 | CACNA1H (0.48) | CYP11B2 | |
| SCHEMBL29889316 | 0.66 | CACNA1H (0.48) | CYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118324767-A | Diacylglycerol kinase modulating compounds | 卡尔那生物科学株式会社 | 2024-07-12 | — | — | CN | disclosed |
| US-20240182476-A1 | DIACYLGLYCEROL KINASE MODULATING COMPOUNDS | GILEAD SCIENCES, INC. | 2024-06-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240182476-A1 | DIACYLGLYCEROL KINASE MODULATING COMPOUNDS | DGKG, DGKB, DGKK | HRH4 3793/4885CDC7 83/4885CYP11B2 4258/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.